Research programme: atherosclerosis therapies - AbbVie/Arisaph Pharmaceuticals

Drug Profile

Research programme: atherosclerosis therapies - AbbVie/Arisaph Pharmaceuticals

Alternative Names: ARI-1778; KH 01503; Rev D-4F; Reverse D-4F

Latest Information Update: 13 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Arisaph Pharmaceuticals; Kos Pharmaceuticals
  • Class
  • Mechanism of Action Apolipoprotein A I stimulants; Lipase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Atherosclerosis

Most Recent Events

  • 13 Oct 2015 Preclinical development is ongoing in the USA
  • 13 Sep 2007 Preclinical development is ongoing
  • 13 Dec 2006 Kos Pharmaceuticals has been acquired by Abbott Laboratories
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top